• Galmed entered collaboration with Tissue Dynamics to build human cardiac fibrosis platform aimed at advancing Aramchol-based therapeutics.
• Program targets chronic post-myocardial infarction remodeling, also HFpEF, using vascularized multichamber cardiac organoids with embedded metabolic sensors.
• DynamiX platform designed to run more than 20,000 organoids in parallel, generating longitudinal readouts to support candidate selection, dosing strategy, combinations, and stage-specific interventions.
• Effort centers on links between lipid metabolism, SCD1 activity, fibrosis, impaired tissue repair, positioning platform as preclinical engine for new cardiac fibrosis drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060730PR_NEWS_USPR_____LN52545) on May 06, 2026, and is solely responsible for the information contained therein.